This compound is a modified phosphoramidite building block used in the chemical synthesis of oligonucleotides. It incorporates a constrained ethyl (cEt) modification and a 5-methyluridine (m5U) base, which are designed to enhance the stability and binding properties of synthetic nucleic acids.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1197033-22-9
5'-ODMT cET-uridine 3'-OCE amidite
pharmaceutical intermediate
Dmt-loct phosphoramidite
research compound
1-(2,5-Anhydro-4-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-3-O-{(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl}-6-deoxy-alpha-L-mannofuranosyl)-4-benzamido-5-methylpyrimidin-2(1H)-one
pharmaceutical intermediate
2'-O-Propargyl g(iBu)-3'-phosphoramidite
pharmaceutical intermediate
N2-iBu-5'-O-DMTr-2'-O-hexadecanyl guanosine 3'-CED
pharmaceutical intermediate
Methyl 16-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-2-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-3-yl]oxyhexadecanoate
pharmaceutical intermediate
(1R,3R,4R,7S)-1-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-(2-(((dimethylamino)methylene)amino)-6-oxo-3H-purin-9(6H)-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl (2-cyanoethyl) diisopropylphosphoramidite
pharmaceutical intermediate
(3R,4S)-4-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-((trimethylsilyl)oxy)propyl)azetidin-2-one
pharmaceutical intermediate
3-[[(1S,3R,4R,6S,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-6-methyl-3-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile
SEFBXGXPINACNI-IMMRMUFKSA-N
C[C@H]1[C@]2([C@H]([C@@H](O1)[C@@H](O2)N3C=C(C(=O)NC3=O)C)OP(N(C(C)C)C(C)C)OCCC#N)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC